A lawyer for MedImmune Inc. asked the Supreme Court yesterday to let the company sue to overturn a patent owned by Genentech Inc. on a component of MedImmune's blockbuster drug Synagis, even though MedImmune is paying royalties to use it. The U.S. Court of Appeals for the Federal Circuit, which has jurisdiction over patent law, blocked MedImmune from suing in 2004, ruling that a 1998 deal that MedImmune agreed to with Genentech amounted to a recognition of its patent's validity, leaving no genuine conflict for the courts to resolve. ....